ProMIS Neurosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-39.72	2.78	-13.21	-18.06	-9.79
Depreciation & Amortization	-	-	0.02	0.01	0.05
Other Amortization	-	-	-	0.24	0.37
Loss (Gain) From Sale of Assets	-	-	-	-	-0.06
Stock-Based Compensation	0.86	0.83	0.27	0.49	0.52
Other Operating Activities	-0.01	-19.06	-0.87	-5.11	1.18
Change in Accounts Payable	0.81	-6.11	4.96	2.68	-0.03
Change in Other Net Operating Assets	9.94	-5.62	-2.02	2.73	-1.53
Operating Cash Flow	-28.12	-27.18	-10.84	-17.03	-9.31
Capital Expenditures	-	-	-	-0	-0.01
Sale of Property, Plant & Equipment	-	-	-	-	0.1
Investment in Securities	-0	-0	-0	-	0
Investing Cash Flow	-0	-0	-0	-0	0.09
Long-Term Debt Issued	-	-	-	-	6.92
Total Debt Issued	-	-	-	-	6.92
Net Debt Issued (Repaid)	-	-	-	-	6.92
Issuance of Common Stock	10.08	27.88	17.75	4.97	15.87
Other Financing Activities	10.87	-	-	1.52	2.74
Financing Cash Flow	20.94	27.88	17.75	6.49	25.52
Foreign Exchange Rate Adjustments	-	-	-0.18	-0.53	-0.18
Net Cash Flow	-7.17	0.69	6.72	-11.07	16.14
Free Cash Flow	-28.12	-27.18	-10.84	-17.04	-9.31
Free Cash Flow Per Share	-16.00	-25.68	-22.05	-56.77	-40.23
Cash Interest Paid	-	0.08	0.2	-	-
Levered Free Cash Flow	-13.32	-21.47	-5.32	-8.01	-6.11
Unlevered Free Cash Flow	-13.32	-21.42	-5.19	-8.07	-6.22
Change in Working Capital	10.75	-11.73	2.94	5.4	-1.56

Updated Mar 25, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q